依达拉奉右莰醇联合替罗非班对急性进展性脑梗死患者神经功能及认知功能的影响

Effects of Edaravone Dextranol Combined with Tirofiban on Neurological Function and Cognitive Function in Patients with Acute Progressive Cerebral Infarction

目的研究依达拉奉右莰醇联合替罗非班对急性进展性脑梗死患者神经功能及认知功能的影响.方法选择2021年11月—2022年11月我院收治的75例急性进展性脑梗死患者为研究对象,按不同治疗方法分为两组.对照组(n=38)采用替罗非班治疗,观察组(n=37)采用依达拉奉右莰醇联合替罗非班治疗,均连续治疗14 d.比较两组患者的临床疗效、血清神经因子、神经功能、认知功能及不良反应发生情况.结果观察组的治疗总有效率为91.89%,高于对照组的73.68%,差异有统计学意义(P<0.05).治疗后,观察组的碱性成纤维细胞生长因子、脑源性神经营养因子水平均高于对照组,神经元特异性烯醇化酶水平低于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的美国国立卫生研究院卒中量表评分低于对照组,简易智力状态检查量表评分、蒙特利尔认知评估量表评分均高于对照组,组间差异有统计学意义(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论急性进展性脑梗死患者采用依达拉奉右莰醇联合替罗非班治疗的效果确切,可改善其神经功能及认知功能,安全可靠.

Objective To study the effects of edaravone dextranol combined with tirofiban on neurological function and cognitive function in patients with acute progressive cerebral infarction.Methods 75 patients with acute progressive cerebral infarction admitted to the hospital from November 2021 to November 2022 were selected as the research objects and were divided into two groups according to different treatment methods.The control group(n=38)was treated with tirofiban,and the observation group(n=37)was treated with edaravone dextranol combined with tirofiban.Both groups were treated continuously for 14 days.The clinical efficacy,serum neurofactors,neurological function,cognitive function and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 91.89%,which was higher than 73.68%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of basic fibroblast growth factor and brain-derived neurotrophic factor in the observation group were higher than those in the control group,while the neuron-specific enolase level was lower than that in the control group,the differences between the groups were statistically significant(P<0.05).After treatment,the National Institutes of Health stroke scale score in the observation group was lower than that in the control group,and the scores of the mini-mental state examination and the Montreal cognitive assessment were higher than those in the control group,the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Edaravone dextranol combined with tirofiban is effective in the treatment of patients with acute progressive cerebral infarction,and can improve their neurological and cognitive functions,which is safe and reliable.